Patents Assigned to Vernagen, LLC
  • ENGINEERED HEARTLAND VIRUS MRNA VACCINE
    Publication number: 20240189414
    Abstract: Provided herein are a Heartland virus vaccine composition including a messenger ribonucleic acid (mRNA) including an open reading frame (ORF) encoding Gn or Gc of Heartland virus, a Heartland virus vaccine composition comprising a messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding Gn or Gc of Heartland virus fused with human collagen type I alpha 1 (COL1A1) signal peptide, and a method of inducing immune response against Heartland virus by administering an effective amount of the Heartland virus vaccine composition to a subject in need thereof.
    Type: Application
    Filed: December 6, 2023
    Publication date: June 13, 2024
    Applicants: Vernagen, LLC, The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Baek KIM, Jack Yoon, David Pak, Claire Yuhui Huang Kinney
  • ENGINEERED VARICELLA ZOSTER VIRUS SHINGLES MRNA VACCINE
    Publication number: 20240148861
    Abstract: Provided herein are a shingles vaccine composition including a messenger ribonucleic acid (mRNA) including an open reading frame (ORF) encoding varicella Zoster virus (VZV) glycoprotein E (gE)(which is soluble VZV gE or full-length VZV gE) and a method of inducing immune response against Shingles by administering an effective amount of the Shingles vaccine composition to a subject in need thereof.
    Type: Application
    Filed: November 8, 2023
    Publication date: May 9, 2024
    Applicant: Vernagen, LLC
    Inventors: Baek KIM, Jack Yoon, David Pak